GlassScriptPhysician profile
Christopher P Shaver
NPI 1407800378
$4,379.15
in general payments reported to CMS, 2019-2025
24 companies · $747 in 2025
The $747 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $207 · 2021: $537 · 2022: $723 · 2023: $642 · 2024: $963 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,334 · Education: $17.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,334.46 |
| Education | $17.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,487.40 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $877.19 | 2019-2025 | Stelara, Tremfya |
| Abbvie INC. | $650.41 | 2019-2025 | Rinvoq, Viberzi, Linzess |
| Pfizer INC. | $506.54 | 2019-2025 | |
| Celgene Corporation | $417.20 | 2022-2024 | Zeposia |
| Celltrion USA INC. | $71.36 | 2024-2025 | Vegzelma, Zymfentra |
| Intercept Pharmaceuticals, INC. | $44.39 | 2023-2024 | Ocaliva |
| Ucb, INC. | $37.78 | 2019-2020 | |
| Medtronic USA, INC. | $30.59 | 2019 | |
| Enterra Medical, INC. | $29.99 | 2022 | |
| Ironwood Pharmaceuticals, INC | $28.54 | 2023 | Linzess |
| Allergan, INC. | $24.06 | 2019 | |
| Evoke Pharma, INC. | $23.60 | 2024 | |
| Alnylam Pharmaceuticals INC. | $20.70 | 2022 | |
| Genzyme Corporation | $20.68 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $18.02 | 2023 | Rebyota |
| Novo Nordisk INC | $16.57 | 2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $15.80 | 2025 | Entyvio |
| Boston Scientific Corporation | $13.05 | 2019 | |
| Nestle Healthcare Nutrition INC. | $12.52 | 2022 | |
| Phathom Pharmaceuticals, INC. | $11.25 | 2025 | Voquezna |
| Qol Medical, LLC | $11.24 | 2019 | |
| Thd America, INC. | $5.32 | 2022 | |
| Kinex Medical Company LLC | $4.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Shaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.